Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
Date:5/9/2011

o advance the drug in longer term extensions in preparation for Phase 3 development.  Our next-generation URAT1 inhibitor program is currently in preclinical development. BAY 86-9766 (RDEA119), is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare AG. BAY 86-9766 is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib (Nexavar®; Bayer, Onyx Pharmaceuticals) and a Phase 1/Phase 2 study in patients with advanced pancreatic cancer in combination with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad (RDEA594), BAY 86-9766 (RDEA119) and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."  All forward-l
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
2. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
3. Ardea Biosciences Prices Public Offering of Common Stock
4. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
5. Ardea Biosciences to Present at Two Upcoming Investor Conferences
6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
8. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
10. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
11. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... According to population studies: “North Carolina ... and 2030." If a population explosion like that actually ... state in the country. , To that end, North ... of North Carolina Forum on December 16th to ask ... necessary infrastructure in place? Enough clean water? And will ...
(Date:12/13/2014)... 2014  Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company ... Veronica G. H. Jordan , Ph.D., and ... Directors, bringing the total number of directors to eight, ... Jim LaFrance , Chairman, President, and Chief Executive Officer ... the appointments of Veronica and David to our board ...
(Date:12/13/2014)... 12, 2014  Vaccinex Inc., a clinical-stage ... development of therapeutic monoclonal antibodies to treat ... of a manuscript entitled "SEMA4D compromises blood–brain ... neurodegenerative disease" in the January 2015 issue ... publication highlights an important role for antibodies ...
(Date:12/12/2014)... Schlieren, Switzerland (PRWEB) December 11, 2014 ... for toxicity and efficacy testing, announced today that data ... InSphero’s 3D liver microtissues as a more predictive model ... Findings presented at the 2nd Annual Functional Analysis ... project to assess the response of InSphero’s 3D ...
Breaking Biology Technology:North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 3
...  Ambit Biosciences today announced that Michael A. Martino, Ambit,s president ... company and an update about its clinical development programs, including ... in New York City. , 14th Annual BIO ... on Monday, February 13, 2012 , Leerink Swann ...
... 9, 2012  Micross Components, a leading global provider ... to announce its participation in the "Drive for ... Electronics. Included as a "pit stop" during the ... selected because of its role in powering innovation ...
... Inc. (NYSE Amex: CUR ) announces that President ... BIO CEO & Investor Conference 2012 in New York City ... present a business overview, and an update on the company,s ... divisions. (Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) ...
Cached Biology Technology:Ambit Biosciences to Present at Two Upcoming Investor Conferences 2Micross Components Hosts Stop on "Drive for Innovation" Tour 2Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012 2Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012 3
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2
... purifiers that produce even small quantities of ozone may ... same time as household cleaning products, scientists at UC ... reacts in the air with unsaturated volatile organic compounds ... that gives them a lemon fragrance ?to create additional ...
... will hold a meeting in Toronto to gather information on ... further introductions of nonindigenous aquatic species into the lakes by ... will comment on the strengths and weaknesses of various options ... DETAILS: 9 a.m. to 5:30 p.m. on May 7 ...
... a single dose, blocks the brain’s ability to strengthen connections ... in Nature. , The findings, uncovered in the laboratory of ... addiction in the brain. The research also supports a provocative ... memory. , "We’ve added a new piece to the ...
Cached Biology News:In presence of fragrant cleaning products, air purifiers that emit ozone can dirty the air 2Morphine makes lasting -- and surprising -- change in the brain 2
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Feline Rhinotracheitis Virus...
Rabbit anti-NFkB p105/p50 (Ser529) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: